SavedAdd your journal

Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2022 / Cilt: 56 - Sayı: 2

Favipiravir Experience in COVID-19 Patients at a Tertiary Center Intensive Care Unit

Mustafa ALTINAY
Ayşe SURHAN ÇINAR
Serkan İSLAMOĞLU
Sultan ACAR SEVİNÇ
Nermin BALTA BAŞI
Seyhan METİN
Tuğba YÜCEL
Hacı Mustafa ÖZDEMİR
Pages
189–195
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Objectives: The aim of this study was to compare intensive care unit (ICU) and overall hospital mortality in patients treated with favipiravir and lopinavir-ritonavir for COVID-19.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The aim of this study was to compare intensive care unit (ICU) and overall hospital mortality in patients treated with favipiravir and lopinavir-ritonavir for COVID-19.
📊
Key Findings & Data:Methods: Data were collected retrospectively between March 10 and May 10, 2020, from patients’ records admitted to ICU due to COVID-19.
💡
Conclusion & Impact:Favipiravir needs more attention and trials for its effect to be confirmed.
🔬Design:Research Article
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: The aim of this study was to compare intensive care unit (ICU) and overall hospital mortality in patients treated with favipiravir and lopinavir-ritonavir for COVID-19. Methods: Data were collected retrospectively between March 10 and May 10, 2020, from patients’ records admitted to ICU due to COVID-19. Laboratory data, clinical characteristics, ICU and hospital mortality, ICU and hospital length of stay were compared in patients treated with favipiravir and lopinavir-ritonavir. Results: A total of 100 patients’ data were investigated. Favipiravir was used as the treatment for 85% of patients, with the rest treated with lopinavir-ritonavir. Clinical and laboratory data of both antiviral treatment groups were similar. Length of hospital stay was 16 (9–24) days with favipiravir and 8.5 (5–12.5) days with lopinavir-ritonavir (p=0.002). Length of ICU stay for favipiravir and lopinavir-ritonavir groups were 8 (5–15) days and 4 (3–9) days, respectively (p=0.011). ICU mortality was 65.9% for the favipiravir and 80% for lopinavir-ritonavir (p=0.002). Hospital mortality for favipiravir and lopinavir-ritonavir was 67.1% and 80%, respectively (p=0.001). Conclusion: The mortality in patients treated with favipiravir was less than patients treated with lopinavir-ritonavir. Favipiravir needs more attention and trials for its effect to be confirmed.

🔖

Cite This Article

ALTINAY, M., ÇINAR, A. S., İSLAMOĞLU, S., SEVİNÇ, S. A., BAŞI, N. B., METİN, S., YÜCEL, T., ÖZDEMİR, H. M. (2022). Favipiravir Experience in COVID-19 Patients at a Tertiary Center Intensive Care Unit. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 56 - Sayı: 2, 189–195. https://ajindex.com/articles/594623

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Stringer KA, Puskarich MA, Kenes MT, Dickson RP. COVID-19: The uninvited guest in the intensive care unit - implications for pharmacotherapy. Pharmacotherapy 2020;40:382–6
  2. Republic of Turkey Ministry of Health Directorate General of Public Health. COVID-19 (SARS-CoV-2 INFECTION) GUIDE Study of Scientific Board. Available at: https://hsgm.saglik.gov.tr/ depo/birimler/goc_sagligi/covid19/rehber/COVID-19_Rehberi20200414_eng_v4_002_14.05.2020.pdf. Accessed Apr 22, 2022
  3. Du YX, Chen XP. Favipiravir: Pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther 2020;108:242–7
  4. Yamamoto N, Matsuyama S, Hoshino T, Yamamoto N. Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. bioRxiv April 08, 2020, doi: 10.1101/2020.04.06.026476
  5. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013;100:446–54
  6. Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther 2020;209:107512
  7. Section 2: AKI Definition. Kidney Int Suppl (2011) 2012;2:19–36
  8. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China. JAMA 2020;323:1061–9
  9. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al; COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020;323:1574– 81
  10. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med 2020;288:192–206
  11. Zheng Y, Sun LJ, Xu M, Pan J, Zhang YT, Fang XL, et al. Clinical characteristics of 34 COVID-19 patients admitted to intensive care unit in Hangzhou, China. J Zhejiang Univ Sci B 2020;21:378– 87
  12. Mitra AR, Fergusson NA, Lloyd-Smith E, Wormsbecker A, Foster D, Karpov A, et al. Baseline characteristics and outcomes of patients with COVID-19 admitted to intensive care units in Vancouver, Canada: a case series. CMAJ 2020;192:E694–701
  13. Ilhan B, Altuntas Y. Optimum management of COVID-19 in the geriatric population: The need for a comprehensive assessment. Sisli Etfal Hastan Tip Bul 2020;54:388–9
  14. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Na